Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis
- PMID:37666449
- DOI: 10.1016/j.cmi.2023.08.029
Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis
Abstract
Background: Cefiderocol is a last resort option for carbapenem-resistant (CR) Gram-negative bacteria, especially metallo-β-lactamase-producing Pseudomonas aeruginosa and CR Acinetobacter baumannii. Monitoring global levels of cefiderocol non-susceptibility (CFDC-NS) is important.
Objectives: To systematically collate and examine studies investigating in vitro CFDC-NS and estimate the global prevalence of CFDC-NS against major Gram-negative pathogens.
Data sources: PubMed and Scopus, up to May 2023.
Study eligibility criteria: Eligible were studies reporting CFDC-NS in Enterobacterales, P. aeruginosa, A. baumannii, or Stenotrophomonas maltophilia clinical isolates.
Risk-of-bias assessment: Two independent reviewers extracted study data and assessed the risk of bias on the population, setting, and measurement (susceptibility testing) domains.
Data synthesis: Binomial-Normal mixed-effects models were applied to estimate CFDC-NS prevalence by species, coresistance phenotype, and breakpoint definition (EUCAST, CLSI, and FDA). Sources of heterogeneity were investigated by subgroup and meta-regression analyses.
Results: In all, 78 studies reporting 82 035 clinical isolates were analysed (87% published between 2020 and 2023). CFDC-NS prevalence (EUCAST breakpoints) was low overall but varied by species (S. maltophilia 0.4% [95% CI 0.2-0.7%], Enterobacterales 3.0% [95% CI 1.5-6.0%], P. aeruginosa 1.4% [95% CI 0.5-4.0%]) and was highest for A. baumannii (8.8%, 95% CI 4.9-15.2%). CFDC-NS was much higher in CR Enterobacterales (12.4%, 95% CI 7.3-20.0%) and CR A. baumannii (13.2%, 95% CI 7.8-21.5%), but relatively low for CR P. aeruginosa (3.5%, 95% CI 1.6-7.8%). CFDC-NS was exceedingly high in New Delhi metallo-β-lactamase-producing Enterobacterales (38.8%, 95% CI 22.6-58.0%), New Delhi metallo-β-lactamase-producing A. baumannii (44.7%, 95% CI 34.5-55.4%), and ceftazidime/avibactam-resistant Enterobacterales (36.6%, 95% CI 22.7-53.1%). CFDC-NS varied considerably with breakpoint definition, predominantly among CR bacteria. Additional sources of heterogeneity were single-centre investigations and geographical regions.
Conclusions: CFDC-NS prevalence is low overall, but alarmingly high for specific CR phenotypes circulating in some institutions or regions. Continuous surveillance and updating of global CFDC-NS estimates are imperative while cefiderocol is increasingly introduced into clinical practice. The need to harmonize EUCAST and CLSI breakpoints was evident.
Keywords: Carbapenem-resistant; Cefiderocol; Drug resistance; Global epidemiology; Gram-negative bacteria; Prevalence.
Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Similar articles
- In vitro activity assessment of cefiderocol against Enterobacterales,Pseudomonas aeruginosa, andAcinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals.Kimbrough JH, Maher JM, Sader HS, Castanheira M, Mendes RE.Kimbrough JH, et al.Microbiol Spectr. 2024 Nov 5;12(11):e0147424. doi: 10.1128/spectrum.01474-24. Epub 2024 Oct 10.Microbiol Spectr. 2024.PMID:39387599Free PMC article.
- In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.Kayama S, Kawakami S, Kondo K, Kitamura N, Yu L, Hayashi W, Yahara K, Sugawara Y, Sugai M.Kayama S, et al.J Glob Antimicrob Resist. 2024 Sep;38:12-20. doi: 10.1016/j.jgar.2024.05.009. Epub 2024 May 22.J Glob Antimicrob Resist. 2024.PMID:38789082
- Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.Delgado-Valverde M, Conejo MDC, Serrano L, Fernández-Cuenca F, Pascual Á.Delgado-Valverde M, et al.J Antimicrob Chemother. 2020 Jul 1;75(7):1840-1849. doi: 10.1093/jac/dkaa117.J Antimicrob Chemother. 2020.PMID:32277821Free PMC article.
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.Zhanel GG, et al.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.Drugs. 2019.PMID:30712199Review.
- Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, Kebriaei R, Rybak MJ.Abdul-Mutakabbir JC, et al.Pharmacotherapy. 2020 Dec;40(12):1228-1247. doi: 10.1002/phar.2476. Epub 2020 Nov 19.Pharmacotherapy. 2020.PMID:33068441Review.
Cited by
- Comparison of Different Methods for Assaying the In Vitro Activity of Cefiderocol against Carbapenem-ResistantPseudomonas aeruginosa Strains: Influence of Bacterial Inoculum.García-Rivera C, Sánchez-Bautista A, Parra-Grande M, Ricart-Silvestre A, Ventero MP, Tyshkovska I, Merino E, Rodríguez Díaz JC.García-Rivera C, et al.Antibiotics (Basel). 2024 Jul 18;13(7):663. doi: 10.3390/antibiotics13070663.Antibiotics (Basel). 2024.PMID:39061345Free PMC article.
- Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.Jean-Pierre V, Sorlin P, Pantel A, Chiron R, Lavigne JP, Jeannot K, Marchandin H; Collaborative study group on antimicrobial resistance of Achromobacter spp..Jean-Pierre V, et al.Ann Clin Microbiol Antimicrob. 2024 Jun 17;23(1):54. doi: 10.1186/s12941-024-00709-z.Ann Clin Microbiol Antimicrob. 2024.PMID:38886694Free PMC article.
- Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory.Russo C, Humphries R.Russo C, et al.Antibiotics (Basel). 2023 Dec 5;12(12):1700. doi: 10.3390/antibiotics12121700.Antibiotics (Basel). 2023.PMID:38136734Free PMC article.Review.
- RESIST ACINETO test for the rapid detection of NDM and OXA acquired carbapenemases directly from blood culture inAcinetobacter species.Potron A, Daniel M, Bay M, Choulet P, Garrigos T, Sababadichetty L, Belmonte O, Fournier D, Jeannot K, Miltgen G.Potron A, et al.Microbiol Spectr. 2024 Oct 3;12(10):e0104424. doi: 10.1128/spectrum.01044-24. Epub 2024 Aug 20.Microbiol Spectr. 2024.PMID:39162506Free PMC article.
- Genomic Insights into Vietnamese Extended-Spectrum β-Lactamase-9-Producing Extensively Drug-ResistantPseudomonas aeruginosa Isolates Belonging to the High-Risk Clone ST357 Obtained from Bulgarian Intensive Care Unit Patients.Strateva T, Stratev A, Peykov S.Strateva T, et al.Pathogens. 2024 Aug 25;13(9):719. doi: 10.3390/pathogens13090719.Pathogens. 2024.PMID:39338911Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous